ArticleFrontiers in oncology2026
Dynamic monitoring of immunoglobulin G as a prognostic indicator after curative resection in high-risk stage II-III colorectal cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable markers for predicting postoperative recurrence in high-risk stage II-III colorectal cancer remain limited. Dynamic changes in immunoglobulin G (IgG) may provide prognostic information beyond carcinoembryonic antigen (CEA). Methods: This single-centre retrospective cohort study included 192 patients with high-risk stage II or III colorectal cancer who underwent curative resection between January 2021 and June 2023. The study evaluated whether dynamic postoperative monitoring of serum IgG predicts 2-year disease-free survival (DFS) compared with CEA. Serial IgG and CEA measurements within 24 months were categorised as favourable or unfavourable trajectories based on predefined thresholds and temporal trends. Patients were further stratified into four groups according to combined IgG and CEA dynamics. Survival was assessed using Kaplan-Meier analysis and Cox regression models. Results: Among 192 eligible patients, 60 (31.3%) experienced recurrence or death within 2 years. Unfavourable IgG trajectories (n=82) were associated with significantly lower 2-year DFS than favourable trajectories (55% [95% CI 44-65] vs 82% [95% CI 73-88], log-rank P<0.01). CEA trajectories showed only borderline separation (67% [95% CI 55-77] vs 79% [95% CI 71-85], log-rank P = 0.06). Patients with both unfavourable IgG and CEA trajectories had the poorest outcomes (2-year DFS 31% [95% CI 16-47]). In multivariable analysis, an unfavourable IgG trajectory independently predicted recurrence or death (HR 2.05, 95% CI 1.32-3.18), whereas CEA trajectory was not significant. Conclusion: Dynamic postoperative IgG monitoring is independently associated with disease recurrence in high-risk stage II-III colorectal cancer and offers incremental prognostic value beyond CEA. Incorporating serial IgG measurements may enhance postoperative risk stratification, although confirmation in prospective multicentre studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.